Baseline gut microbiome and metabolites are correlated with alcohol consumption in a zonisamide clinical trial of heavy drinking alcoholic civilians

Liv R. Dedon,Hanshu Yuan,Jinhua Chi,Haiwei Gu,Albert J. Arias,Jonathan M. Covault,Yanjiao Zhou

DOI: https://doi.org/10.1101/2024.04.02.24305199

2024-04-03

Abstract:Development and severity of alcohol use disorder (AUD) has been linked to variations in gut microbiota and their associated metabolites in both animal and human studies. However, the involvement of the gut microbiome in alcohol consumption of individuals with AUD undergoing treatment remains unclear. To address this, stool samples (n=48) were collected at screening (baseline) and trial completion from a single site of a multi-site double-blind, placebo-controlled trial of Zonisamide in individuals with AUD. Alcohol consumption, gamma-glutamyl transferase (GGT), and phosphatidylethanol (PEth)levels were measured both at baseline and endpoint of 16-week trial period. Fecal microbiome was analyzed 16S rRNA sequencing and metabolome untargeted LC-MS. Both sex (p = 0.003) and psychotropic medication usage (p = 0.025) are associated with baseline microbiome composition. The relative abundance of 12 genera at baseline was correlated with percent drinking reduction, baseline and endpoint alcohol consumption, and changes in GGT and PeTH over the course of treatment (p.adj < 0.05). Overall microbiome community structure at baseline differed between high and low responders (67-100% and 0-33% drinking reduction, respectively; p = 0.03). A positive relationship between baseline fecal GABA levels and percent drinking reduction (R=0.43, p < 0.05) was identified by microbiome function prediction and confirmed by ELISA and metabolomics. Predicted microbiome function and metabolomics analysis have found that tryptophan metabolic pathways are over-represented in low responders. These findings highlight importance of baseline microbiome and metabolites in alcohol consumption in AUD patients undergoing zonisamide treatment.

Addiction Medicine

What problem does this paper attempt to address?

This paper discusses the relationship between baseline gut microbiota and metabolites and alcohol consumption in a clinical trial of zonisamide treatment for severe alcohol dependence. The study found that the baseline gut microbial community structure is related to individual response to treatment (degree of alcohol reduction), particularly in relation to the abundance of 12 genera. Gender and psychotropic drug use also affect the baseline microbiota. There are significant differences in the gut microbial community structure between high responders (67-100% reduction in alcohol consumption) and low responders (0-33% reduction in alcohol consumption). In addition, the level of gamma-aminobutyric acid (GABA) in baseline feces is positively correlated with alcohol reduction, suggesting that gut microbiota may influence alcohol consumption behavior through the regulation of GABA. The study also points out that the tryptophan metabolic pathway is enriched in low responders. These findings emphasize the importance of baseline gut microbiota and metabolites in alcohol consumption and treatment response in alcohol-dependent patients, and may provide potential biomarkers for predicting treatment response.

Baseline gut microbiome and metabolites are correlated with alcohol consumption in a zonisamide clinical trial of heavy drinking alcoholic civilians

Association Between Abnormal Plasma Metabolism and Brain Atrophy in Alcohol-Dependent Patients

Multiomics Analyses Reveal Microbiome–Gut–Brain Crosstalk Centered on Aberrant Gamma-Aminobutyric Acid and Tryptophan Metabolism in Drug-Naïve Patients with First-Episode Schizophrenia

Results from a randomized controlled trial of zonisamide in the treatment of alcohol use disorder

The gut‐brain axis in individuals with alcohol use disorder: An exploratory study of associations among clinical symptoms, brain morphometry, and the gut microbiome

Diet High in Alcohol Impacts the Gut Microbiota and Associated Metabolome (P08-134-19)

Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease

Integrated Analyses of the Gut Microbiota, Intestinal Permeability, and Serum Metabolome Phenotype in Rats with Alcohol Withdrawal Syndrome

Longitudinal gut microbiome changes in alcohol use disorder are influenced by abstinence and drinking quantity

Alterations and correlations of gut microbiota, fecal, and serum metabolome characteristics in a rat model of alcohol use disorder

The gut microbiome in alcohol use disorder and alcohol‐associated liver disease: A systematic review of clinical studies

Alterations of kynurenine pathway in alcohol use disorder and abstinence: a link with gut microbiota, peripheral inflammation and psychological symptoms

Blood metabolomic profiling reveals new targets in the management of psychological symptoms associated with severe alcohol use disorder

Serum metabolomic analysis in cirrhotic alcohol-associated liver disease patients identified differentially altered microbial metabolites and novel potential biomarkers for disease severity

Role of gut microbiota in the biological and behavioral control of alcohol-dependence

Chronic alcohol exposure induced gut microbiota dysbiosis and its correlations with neuropsychic behaviors and brain BDNF/Gabra1 changes in mice

Gut microbiota and voluntary alcohol consumption

The gut-immune-liver axis in patients with alcohol use disorder and clinically low serum zinc levels

Standard rodent diets differentially impact alcohol consumption and preference and gut microbiome diversity

Novel paradigms for the gut–brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder

Role of the Microbiome and the Gut-Brain Axis in Alcohol Use Disorder: Potential Implication for Treatment Development